A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer
Abstract Background Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non‐small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we con...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15115 |
| _version_ | 1797628822235906048 |
|---|---|
| author | Yohei Yabuki Masaki Hanibuchi Eiji Takeuchi Takashi Haku Takanori Kanematsu Naoki Nishimura Yuko Toyoda Atsushi Mitsuhashi Kenji Otsuka Seidai Sato Hisatsugu Goto Hiroto Yoneda Hirokazu Ogino Hiroshi Nokihara Shinohara Tsutomu Yasuhiko Nishioka |
| author_facet | Yohei Yabuki Masaki Hanibuchi Eiji Takeuchi Takashi Haku Takanori Kanematsu Naoki Nishimura Yuko Toyoda Atsushi Mitsuhashi Kenji Otsuka Seidai Sato Hisatsugu Goto Hiroto Yoneda Hirokazu Ogino Hiroshi Nokihara Shinohara Tsutomu Yasuhiko Nishioka |
| author_sort | Yohei Yabuki |
| collection | DOAJ |
| description | Abstract Background Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non‐small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a phase II study to elucidate the efficacy of pemetrexed (PEM) plus bevacizumab (Bev) combination chemotherapy in elderly patients with nonsquamous NSCLC. Methods A total of 29 elderly patients (≥75 years old) with nonsquamous NSCLC were enrolled in this multicenter, open‐label, phase II study, and 27 patients were finally analyzed. PEM at 500 mg/m2 on day 1 plus Bev at 15 mg/kg on day 1 were administered triweekly. The primary endpoint was the investigator‐assessed objective response rate. Results The median age at initiating chemotherapy was 80 years old. Almost all patients (92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression‐free survival, overall survival and 1‐year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well‐tolerated, and no treatment‐related death was observed. Conclusion Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non‐squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. |
| first_indexed | 2024-03-11T10:45:36Z |
| format | Article |
| id | doaj.art-0bcc20ae3023490cbf17233bd45b1ae2 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-11T10:45:36Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-0bcc20ae3023490cbf17233bd45b1ae22023-11-14T05:52:29ZengWileyThoracic Cancer1759-77061759-77142023-11-0114323232323910.1111/1759-7714.15115A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancerYohei Yabuki0Masaki Hanibuchi1Eiji Takeuchi2Takashi Haku3Takanori Kanematsu4Naoki Nishimura5Yuko Toyoda6Atsushi Mitsuhashi7Kenji Otsuka8Seidai Sato9Hisatsugu Goto10Hiroto Yoneda11Hirokazu Ogino12Hiroshi Nokihara13Shinohara Tsutomu14Yasuhiko Nishioka15Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Community Medicine for Respirology, Hematology and Metabolism, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Clinical Investigation National Hospital Organization Kochi Hospital Kochi JapanDepartment of Respiratory Medicine Tokushima Prefectural Central Hospital Tokushima JapanDepartment of Respiratory Medicine Japanese Red Cross Matsuyama Hospital Matsuyama JapanDepartment of Pulmonary Medicine St. Luke's International Hospital Tokyo JapanDepartment of Internal Medicine Japanese Red Cross Kochi Hospital Kochi JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine Center Hospital of the National Center for Global Health and Medicine Tokyo JapanDepartment of Community Medicine for Respirology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima University Tokushima JapanAbstract Background Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non‐small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a phase II study to elucidate the efficacy of pemetrexed (PEM) plus bevacizumab (Bev) combination chemotherapy in elderly patients with nonsquamous NSCLC. Methods A total of 29 elderly patients (≥75 years old) with nonsquamous NSCLC were enrolled in this multicenter, open‐label, phase II study, and 27 patients were finally analyzed. PEM at 500 mg/m2 on day 1 plus Bev at 15 mg/kg on day 1 were administered triweekly. The primary endpoint was the investigator‐assessed objective response rate. Results The median age at initiating chemotherapy was 80 years old. Almost all patients (92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression‐free survival, overall survival and 1‐year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well‐tolerated, and no treatment‐related death was observed. Conclusion Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non‐squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population.https://doi.org/10.1111/1759-7714.15115bevacizumabelderly patientspemetrexedpreviously untreated nonsquamous non‐small cell lung cancer |
| spellingShingle | Yohei Yabuki Masaki Hanibuchi Eiji Takeuchi Takashi Haku Takanori Kanematsu Naoki Nishimura Yuko Toyoda Atsushi Mitsuhashi Kenji Otsuka Seidai Sato Hisatsugu Goto Hiroto Yoneda Hirokazu Ogino Hiroshi Nokihara Shinohara Tsutomu Yasuhiko Nishioka A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer Thoracic Cancer bevacizumab elderly patients pemetrexed previously untreated nonsquamous non‐small cell lung cancer |
| title | A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer |
| title_full | A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer |
| title_fullStr | A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer |
| title_full_unstemmed | A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer |
| title_short | A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer |
| title_sort | multicenter open label phase ii trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non small cell lung cancer |
| topic | bevacizumab elderly patients pemetrexed previously untreated nonsquamous non‐small cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.15115 |
| work_keys_str_mv | AT yoheiyabuki amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT masakihanibuchi amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT eijitakeuchi amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT takashihaku amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT takanorikanematsu amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT naokinishimura amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT yukotoyoda amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT atsushimitsuhashi amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT kenjiotsuka amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT seidaisato amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hisatsugugoto amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hirotoyoneda amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hirokazuogino amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hiroshinokihara amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT shinoharatsutomu amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT yasuhikonishioka amulticenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT yoheiyabuki multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT masakihanibuchi multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT eijitakeuchi multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT takashihaku multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT takanorikanematsu multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT naokinishimura multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT yukotoyoda multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT atsushimitsuhashi multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT kenjiotsuka multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT seidaisato multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hisatsugugoto multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hirotoyoneda multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hirokazuogino multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT hiroshinokihara multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT shinoharatsutomu multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer AT yasuhikonishioka multicenteropenlabelphaseiitrialofpemetrexedplusbevacizumabinelderlypatientswithpreviouslyuntreatedadvancedorrecurrentnonsquamousnonsmallcelllungcancer |